reversed-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Although vitamin A was not confirmed as an essential nutrient and a chemical structure described until the 20th century, written observations of conditions created by deficiency of this nutrient appeared much earlier in history. Sommer classified historical accounts related to vitamin A and/or manifestations of deficiency as follows: "ancient" accounts; 18th- to 19th-century clinical descriptions (and their purported etiologic associations); early 20th-century laboratory animal experiments, and clinical and epidemiologic observations that identified the existence of this unique nutrient and manifestations of its deficiency.
== Targets == MCD peptide has immunotoxic as well as neurotoxic properties due to different active sites of the MCD peptide. The MCD peptide has an immunotoxic effect on mast cells by releasing histamine from these cells. MCD peptide has also been described as a potent modulator of voltage-gated ionic channels. It binds to several subclasses of voltage-gated potassium channels (Kv channels), including Kv1.1, Kv1.6, and less potently to Kv1.2. Accordingly, MCD peptide can act in various regions of rat brain, including cerebellum, brainstem, hypothalamus, striatum, midbrain, cortex, and hippocampus. However, MCD peptide shows no binding activity in the peripheral neuronal system.
Aberrant basal cell carcinoma Acanthoma fissuratum (granuloma fissuratum, spectacle frame acanthoma) Acrospiroma (clear cell hidradenoma, dermal duct tumor, hidroacanthoma simplex, nodular hidradenoma, poroma) Actinic keratosis (senile keratosis, solar keratosis) Adenoid squamous cell carcinoma (pseudoglandular squamous cell carcinoma) Aggressive digital papillary adenocarcinoma (digital papillary adenocarcinoma, papillary adenoma) Apocrine gland carcinoma Apocrine nevus Arsenical keratosis Atrophic actinic keratosis Balanitis plasmacellularis (balanoposthitis chronica circumscripta plasmacellularis, balanitis circumscripta plasmacellularis, plasma cell balanitis, plasma cell vulvitis, vulvitis circumscripta plasmacellularis, Zoon's balanitis, Zoon's erythroplasia, Zoon's vulvitis) Basal cell carcinoma Basaloid follicular hamartoma Basaloid squamous cell carcinoma Birt–Hogg–Dubé syndrome Bowen's disease (squamous cell carcinoma in situ) Brooke–Fordyce syndrome Ceruminoma Cicatricial basal cell carcinoma (morpheaform basal cell carcinoma, morphoeic basal cell carcinoma) Ciliated cyst of the vulva (cutaneous Müllerian cyst, paramesonephric mucinous cyst of the vulva) Clear cell acanthoma (acanthome cellules claires of Degos and Civatte, Degos acanthoma, pale cell acanthoma) Clear cell squamous cell carcinoma (clear cell carcinoma of the skin) Chronic scar keratosis (chronic cicatrix keratosis) Clonal seborrheic keratosis Common seborrheic keratosis (basal cell papilloma, solid seborrheic keratosis) Cowden syndrome (Cowden's disease, multiple hamartoma syndrome) Cutaneous ciliated cyst Cutaneous columnar cyst Cutaneous horn (Cornu cutaneum) Cystic basal cell carcinoma Dermal eccrine cylindroma (cylindroma) Dermatosis papulosa nigra Desmoplastic trichoepithelioma Dilated pore (dilated pore of Winer) Eccrine carcinoma (syringoid carcinoma) Eccrine nevus Epidermal cyst (epidermal inclusion cyst, epidermoid cyst, infundibular cyst, keratin cyst) Epidermal nevus syndrome (Feuerstein and Mims syndrome, Solomon's syndrome) Epidermolytic acanthoma Epithelioma cuniculatum (Ackerman tumor, carcinoma cuniculatum) Eruptive vellus hair cyst Erythroplasia of Queyrat Extramammary Paget's disease Fibroepithelioma Fibroepithelioma of Pinkus Fibrofolliculoma Follicular hybrid cyst (Hybrid cyst) Folliculosebaceous-apocrine hamartoma (follicular-apocrine hamartoma) Folliculosebaceous cystic hamartoma Generalized eruptive keratoacanthoma (generalized eruptive keratoacanthoma of Grzybowski) Giant solitary trichoepithelioma Hidradenoma Hidradenocarcinoma Hidrocystoma (cystadenoma, Moll's gland cyst, sudoriferous cyst) Hydrocarbon keratosis (pitch keratosis, tar keratosis, tar wart) Hyperkeratosis lenticularis perstans (Flegel's disease) Hyperkeratosis of the nipple and areola Hyperkeratotic actinic keratosis Ichthyosis hystrix (ichthyosis hystrix gravior type Lambert, porcupine man, systematized verrucous nevus) Ichthyosis hystrix of Curth–Macklin Infiltrative basal cell carcinoma Inflammatory linear verrucous epidermal nevus Inverted follicular keratosis Irritated seborrheic keratosis (basosquamous cell acanthoma, inflamed seborrheic keratosis) Isthmicoma (infundibuloma, tumor of the follicular infundibulum) Juvenile myelomonocytic leukemia Keratin implantation cyst Keratoacanthoma Keratoacanthoma centrifugum marginatum Large cell acanthoma Lichenoid actinic keratosis Lichenoid keratosis (benign lichenoid keratosis, lichen planus-like keratosis, solitary lichen planus, solitary lichenoid keratosis) Linear verrucous epidermal nevus (linear epidermal nevus, verrucous epidermal nevus) Malignant acrospiroma (spiradenocarcinoma) Malignant mixed tumor (malignant chondroid syringoma) Malignant trichilemmal cyst Mantleoma Marjolin's ulcer Melanoacanthoma (pigmented seborrheic keratosis) Merkel cell carcinoma (cutaneous apudoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, trabecular carcinoma of the skin) Microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) Micronodular basal cell carcinoma Milia en plaque Milium Mixed tumor (chondroid syringoma) Mucinous carcinoma Mucinous nevus (nevus mucinosus) Muir–Torre syndrome Multiple familial trichoepithelioma (Brooke–Spiegler syndrome, epithelioma adenoides cysticum) Multiple keratoacanthomas (Ferguson–Smith syndrome, Ferguson-Smith type of multiple self-healing keratoacanthomas, multiple keratoacanthomas of the Ferguson–Smith type) Multiple minute digitate hyperkeratosis (digitate keratoses, disseminated spiked hyperkeratosis, familial disseminated piliform hyperkeratosis, minute aggregate keratosis) Nevoid basal cell carcinoma syndrome (basal cell nevus syndrome, Gorlin syndrome, Gorlin–Goltz syndrome) Nevus comedonicus (comedo nevus) Nevus comedonicus syndrome Nevus sebaceous (nevus sebaceous of Jadassohn, organoid nevus) Nevus unius lateris Nodular basal cell carcinoma (classic basal cell carcinoma) Paget's disease of the breast Papillary eccrine adenoma (tubular apocrine adenoma) Papillary hidradenoma (hidradenoma papilliferum) Papillomatosis cutis carcinoides (Gottron's carcinoid papillomatosis, papillomatosis cutis carcinoides of Gottron–Eisenlohr) Patch blue nevus (acquired dermal melanocytosis, dermal melanocyte hamartoma) Perifollicular fibroma Phakomatosis pigmentokeratotica Pigmented actinic keratosis Pigmented basal cell carcinoma Pigmented hairy epidermal nevus syndrome Pilar sheath acanthoma Pilonidal sinus (Barber's interdigital pilonidal sinus, pilonidal cyst, pilonidal disease) Porocarcinoma (malignant poroma, eccrine porocarcinoma) Polypoid basal cell carcinoma Pore-like basal cell carcinoma Primary cutaneous adenoid cystic carcinoma Proliferating epidermoid cyst (proliferating epithelial cyst) Proliferating trichilemmal cyst (pilar tumor, proliferating follicular cystic neoplasm, proliferating pilar tumor, proliferating trichilemmal tumor) Pseudocyst of the auricle (auricular endochondrial pseudocyst, cystic chondromalacia, endochondral pseudocyst, intracartilaginous cyst) Pseudoepitheliomatous keratotic and micaceous balanitis PUVA keratosis Rasmussen syndrome Reactional keratosis Reticulated seborrheic keratosis (adenoid seborrheic keratosis) Rodent ulcer (Jacobi ulcer) Schimmelpenning syndrome (Schimmelpenning–Feuerstein–Mims syndrome) Sebaceoma (sebaceous epithelioma) Sebaceous adenoma Sebaceous carcinoma Sebaceous hyperplasia Sebaceous nevus syndrome Seboacanthoma Seborrheic keratosis (seborrheic verruca, senile wart) Seborrheic keratosis with squamous atypia Signet-ring cell squamous cell carcinoma Solitary keratoacanthoma (subungual keratoacanthoma) Solitary trichoepithelioma Spindle cell squamous cell carcinoma (spindle cell carcinoma) Spiradenoma Squamous cell carcinoma Steatocystoma multiplex (epidermal polycystic disease, sebocystomatosis) Steatocystoma simplex (simple sebaceous duct cyst, solitary steatocystoma) Stucco keratosis (digitate seborrheic keratosis, hyperkeratotic seborrheic keratosis, keratosis alba, serrated seborrheic keratosis, verrucous seborrheic keratosis) Superficial basal cell carcinoma (superficial multicentric basal cell carcinoma) Syringadenoma papilliferum (syringocystadenoma papilliferum) Syringofibroadenoma (acrosyringeal nevus of Weedon and Lewis) Syringoma Systematized epidermal nevus Thermal keratosis Trichilemmal carcinoma Trichilemmal cyst (isthmus-catagen cyst, pilar cyst) Trichilemmoma Trichoadenoma (trichoadenoma of Nikolowski) Trichoblastoma Trichoblastic fibroma Trichodiscoma Trichofolliculoma Unilateral palmoplantar verrucous nevus Urethral caruncle Verrucous carcinoma Verrucous cyst (cystic papilloma) Viral keratosis Warty dyskeratoma (isolated dyskeratosis follicularis) Waxy keratosis of childhood (kerinokeratosis papulosa) Zoon's vulvitis Zosteriform speckled lentiginous nevus
== Usage and consumption == Chocolate is sold in chocolate bars, which come in dark chocolate, milk chocolate and white chocolate varieties. Some bars that are mostly chocolate have other ingredients blended into the chocolate, such as nuts, raisins, or crisped rice. Chocolate is used as an ingredient in a huge variety of bars, which typically contain various confectionary ingredients (e.g., nougat, wafers, caramel, nuts) which are coated in chocolate.
Only two divisions (43rd and 53rd), two armoured brigades, and a parachute brigade were to remain allocated for NATO and the defence of Western Europe; the other eight divisions were placed on a lower establishment for home defence only. The territorial units of the Royal Armoured Corps were also reduced in number to nine armoured regiments and eleven reconnaissance regiments. This was effected by the amalgamation of pairs of regiments, and the conversion of four RAC units to an infantry role. The new parachute brigade group become the 44th Independent Parachute Brigade Group. British forces contracted dramatically as the end of conscription in 1960 came in sight as announced in the 1957 Defence White Paper. On 20 July 1960, a reorganisation of the TA was announced in the House of Commons. The territorials were to be reduced from 266 fighting units to 195. There was to be a reduction of 46 regiments of the Royal Artillery, 18 battalions of infantry, 12 regiments of the Royal Engineers and two regiments of the Royal Corps of Signals. The reductions were carried out in 1961, mainly by amalgamating units. Thus, on 1 May 1961, the TA divisional headquarters were merged with regular army districts, which were matched with Civil Defence Regions to aid mobilisation for war. The Army Reserve Act of April 1962 made provision for a new TA Emergency Reserve (TAER), within existing TA units, who could be called out without Royal Proclamation as individuals to reinforce regular units around the world, for up to six months in every twelve.
Sources: en.wikipedia.org
On 3 December 2004, the twentieth anniversary of the disaster, a man falsely claiming to be a Dow representative named Jude Finisterra was interviewed on BBC World News. He claimed that the company had agreed to clean up the site and compensate those harmed in the accident, by liquidating Union Carbide for US$12 billion. Dow quickly issued a statement saying that they had no employee by that name—that he was an impostor, not affiliated with Dow, and that his claims were a hoax. The BBC later broadcast a correction and an apology. Jude Finisterra was actually Andy Bichlbaum, a member of the activist prankster group The Yes Men. In 2002, The Yes Men issued a fake press release explaining why Dow refused to take responsibility for the disaster and started up a website, at "DowEthics.com", designed to look like the real Dow website, but containing false information.
Patients should be advised to remove any medicated patch prior to an MRI scan and replace it with a new patch after the scan is complete. In 2009, an article in Europace journal detailed stories of skin burns that occurred with transdermal patches that contain metal (usually as a backing material) caused by shock therapy from external as well as internal cardioverter defibrillators (ICD).
Its main constituents are (1) reaction scheme, (2) target of project & deliverables (product, quantity, required dates, specifications), (3) list of analytical methods, (4) process development opportunities (stepwise assessment), (5) list of required reports, (6) Safety, Health and Environment (SHE) issues, (7) materials to be supplied by customer and (8) packaging & shipping information. The technical part of a project usually determines its duration. Depending on the quality of the information contained in the "technology package" received from the customer and the complexity of the project as such, particularly the number of steps that have to be performed, it can be anywhere from 12 to 24 months. Depending on the amount of research involved, the total budget easily amounts to several million US dollars.
== Choanoflagellates == All animals are posited to have evolved from a flagellated eukaryote. Their closest known living relatives are the choanoflagellates, collared flagellates whose cell morphology is similar to the choanocyte cells of certain sponges. Molecular studies place animals in a supergroup called the opisthokonts, which also includes the choanoflagellates, fungi, and a few small parasitic protists. The name comes from the posterior location of the flagellum in motile cells, such as most animal spermatozoa, whereas other eukaryotes tend to have anterior flagella instead.
MGM-15, also known as dihydro-7-hydroxy mitragynine, DH-7OH-MIT is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the Southeast Asian tree kratom. MGM-15 was first reported in 2014. It is the 1,2-dihydro derivative of 7-hydroxymitragynine and shows higher potency as an agonist of the μ-opioid receptor and δ-opioid receptor compared to 7-hydroxymitragynine itself. MGM-15 has been sold as a designer drug since early 2025, initially in the US.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.